362 related articles for article (PubMed ID: 35325068)
1. Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer.
Peipp M; Klausz K; Boje AS; Zeller T; Zielonka S; Kellner C
Clin Exp Immunol; 2022 Jul; 209(1):22-32. PubMed ID: 35325068
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
[TBL] [Abstract][Full Text] [Related]
4. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
5. Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.
Zhang Z; Su T; He L; Wang H; Ji G; Liu X; Zhang Y; Dong G
Tohoku J Exp Med; 2012 Jan; 226(1):59-68. PubMed ID: 22189020
[TBL] [Abstract][Full Text] [Related]
6. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions.
Garcia-Iglesias T; Del Toro-Arreola A; Albarran-Somoza B; Del Toro-Arreola S; Sanchez-Hernandez PE; Ramirez-Dueñas MG; Balderas-Peña LM; Bravo-Cuellar A; Ortiz-Lazareno PC; Daneri-Navarro A
BMC Cancer; 2009 Jun; 9():186. PubMed ID: 19531227
[TBL] [Abstract][Full Text] [Related]
7. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
Lutz S; Klausz K; Albici AM; Ebinger L; Sellmer L; Teipel H; Frenzel A; Langner A; Winterberg D; Krohn S; Hust M; Schirrmann T; Dübel S; Scherließ R; Humpe A; Gramatzki M; Kellner C; Peipp M
Front Immunol; 2023; 14():1227572. PubMed ID: 37965326
[TBL] [Abstract][Full Text] [Related]
8. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias.
Nowbakht P; Ionescu MC; Rohner A; Kalberer CP; Rossy E; Mori L; Cosman D; De Libero G; Wodnar-Filipowicz A
Blood; 2005 May; 105(9):3615-22. PubMed ID: 15657183
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the Expression of Surface Receptors on NK Cells and NKG2D on Immunocytes in Peripheral Blood of Patients with Nasopharyngeal Carcinoma.
Xu Y; Zhou R; Huang C; Zhang M; Li J; Zong J; Qiu S; Lin S; Chen H; Ye Y; Pan J
Asian Pac J Cancer Prev; 2018 Mar; 19(3):661-665. PubMed ID: 29580037
[TBL] [Abstract][Full Text] [Related]
10. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
Smits NC; Coupet TA; Godbersen C; Sentman CL
Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
[TBL] [Abstract][Full Text] [Related]
11. Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells.
Kiefer A; Prüfer M; Röder J; Pfeifer Serrahima J; Bodden M; Kühnel I; Oberoi P; Wels WS
Cells; 2024 Jan; 13(3):. PubMed ID: 38334638
[TBL] [Abstract][Full Text] [Related]
12. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
13. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.
Moretta A; Bottino C; Vitale M; Pende D; Cantoni C; Mingari MC; Biassoni R; Moretta L
Annu Rev Immunol; 2001; 19():197-223. PubMed ID: 11244035
[TBL] [Abstract][Full Text] [Related]
14. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
Kim JY; Bae JH; Lee SH; Lee EY; Chung BS; Kim SH; Kang CD
J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537
[TBL] [Abstract][Full Text] [Related]
15. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR
Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567
[TBL] [Abstract][Full Text] [Related]
16. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.
Peipp M; Derer S; Lohse S; Staudinger M; Klausz K; Valerius T; Gramatzki M; Kellner C
Oncotarget; 2015 Oct; 6(31):32075-88. PubMed ID: 26392331
[TBL] [Abstract][Full Text] [Related]
17. Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer.
Han B; Mao FY; Zhao YL; Lv YP; Teng YS; Duan M; Chen W; Cheng P; Wang TT; Liang ZY; Zhang JY; Liu YG; Guo G; Zou QM; Zhuang Y; Peng LS
J Immunol Res; 2018; 2018():6248590. PubMed ID: 30255106
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
19. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
20. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
